K-ASSAY ®
for a range of rare and orphan diseases, which continue to be an important area of investment for CGT. However, cell and gene therapies for broader indications like diabetes and solid tumors is where the industry is going. Addressing larger patient populations, possibly with single dose therapies, brings enormous benefits to affected patients; however, healthcare provider and payer systems are not currently set up for this new treatment paradigm.
How are biotechnology companies addressing cell and gene therapies manufacturing capacity constraints? A fundamental and unique challenge faced in CGT manufacturing is the highly manual, aseptic, and complex nature of the manufacturing process itself. There are also challenges asso- ciated with scaling lab-developed processes so these therapies can be produced outside the lab at therapeuti- cally relevant doses. Our biotech partners turn to us at
Thermo Fisher to help them automate and standardize approaches so they can achieve scale and avoid poten- tial failures further down the road. While our partners are working on developing cutting edge treatments, our focus is on continually innovating to help drive cost down and shorten timelines so once these treatments are approved, they can be made accessible to patients.
What advice do you have for women aspiring to leadership roles in the life sciences? More than a role, leadership is a set of qualities and behaviors that can be cultivated. Though more natural to some, I’ve seen excellent examples of leadership at all organizational levels, the common denominator being an ability to inspire and drive people toward a common goal. The path for getting to a formal leadership position is as varied as the leadership styles themselves. For me, I leaned in on the technical side, pursuing a PhD in pharmacology, carving a path from bench scientist to product manager, business development to marketing and sales roles. The critical learnings on the way for me was to anchor on my core beliefs, know my strengths and blind spots, and be willing to take calculated risks that pushed me out of my comfort zone. Now with Thermo Fisher for nearly 20 years, I’ve grown with the company, serving in a variety of technical, commercial, and busi- ness leadership roles at the divisional and corporate levels.
D-1 Acid Glycoprotein D-1 Anti-Trypsin
H. pylori Antibody Haptoglobin
D-1 Microglobulin Anti-Streptolysin O Apolipoprotein AI, B, E Apolipoprotein AII, CII, CII
E-2 Microglobulin Complement C3, C4
CRP, hs-CRP Cystatin C D-Dimer Factor XIII Ferritin
Fibrinogen
Hemoglobin A1c IgA, IgG, IgM, IgE Krebs von den Lungen-6 Lipoprotein(a) Microalbumin Microtransferrin Prealbumin
Remnant Lipo. Cholesterol Retinol Binding Protein Rheumatoid Factor Transferrin UIBC
KAMIYA BIOMEDICAL COMPANY A
Group Company
www.k-assay.com
Replacement Reagents for your chemistry analyzer
WHY SWITCH?
Better performance Lower cost
Expanded test menu
Outstanding customer support
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
